Drugs /
lcl161
Overview
Clinical Trials
Lcl161 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating lcl161, 2 are phase 1 (1 open) and 1 is phase 2 (1 open).
ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for lcl161 clinical trials.
Breast carcinoma, colorectal carcinoma, and multiple myeloma are the most common diseases being investigated in lcl161 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.